Can artificial intelligence predict clinical trial outcomes?
This study evaluates the performance of large language models (LLMs) and the HINT model in predicting clinical trial outcomes, focusing on metrics including Balanced Accuracy, Matthews Correlation Coefficient (MCC), Recall, and Specificity. Results show that GPT-4o achieves superior overall performance among LLMs but, like its counterparts (GPT-3.5, GPT-4mini, Llama3), struggles with identifying negative outcomes. In contrast, HINT excels in negative sample recognition and demonstrates resilience to external factors (e.g., recruitment challenges) but underperforms in oncology trials, a major component of the dataset. LLMs exhibit strengths in early-phase trials and simpler endpoints like Overall Survival (OS), while HINT shows consistency across trial phases and excels in complex endpoints (e.g., Objective Response Rate). Trial duration analysis reveals improved model performance for medium- to long-term trials, with GPT-4o and HINT displaying stability and enhanced specificity, respectively. We underscore the complementary potential of LLMs (e.g., GPT-4o, Llama3) and HINT, advocating for hybrid approaches to leverage GPT-4o's predictive power and HINT's specificity in clinical trial outcome forecasting.
Code (0)
등록된 구현이 없습니다.
Tasks
SpecificityMethods 이 논문이 사용한 방법론
Similar Papers 제목 키워드 기반
Advancing clinical trial outcomes using deep learning and predictive modelling: bridging precision medicine and patient-centered care
The integration of artificial intelligence [AI] into clinical trials has revolutionized the process of drug development and personalized medicine. Among these advancements, deep learning and predictive modelling have eme…
Computational EfficiencySurvival AnalysisTime Series ForecastingDevelopment and Validation of a Deep-Learning Model for Differential Treatment Benefit Prediction for Adults with Major Depressive Disorder Deployed in the Artificial Intelligence in Depression Medication Enhancement (AIDME) Study
INTRODUCTION: The pharmacological treatment of Major Depressive Disorder (MDD) relies on a trial-and-error approach. We introduce an artificial intelligence (AI) model aiming to personalize treatment and improve outcomes…
Bayesian Optimizationfeature selectionChemistry42: An AI-based platform for de novo molecular design
Chemistry42 is a software platform for de novo small molecule design that integrates Artificial Intelligence (AI) techniques with computational and medicinal chemistry methods. Chemistry42 is unique in its ability to gen…
Drug DiscoveryCT-ADE: An Evaluation Benchmark for Adverse Drug Event Prediction from Clinical Trial Results
Adverse drug events (ADEs) significantly impact clinical research, causing many clinical trial failures. ADE prediction is key for developing safer medications and enhancing patient outcomes. To support this effort, we i…
TrialBench: Multi-Modal Artificial Intelligence-Ready Clinical Trial Datasets
Clinical trials are pivotal for developing new medical treatments, yet they typically pose some risks such as patient mortality, adverse events, and enrollment failure that waste immense efforts spanning over a decade. A…